FX-909 has achieved clinical proof of concept in the Phase 1A trial as a monotherapy, and we are very pleased to announce this agreement with Merck to add a combination arm to our ongoing Phase 1 ...
The cancer vaccine IO102-IO103 plus Keytruda was associated with a clinically relevant improvement in median progression-free ...
KEYTRUDA is indicated for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then ...
A label expansion for Keytruda in platinum-resistant ovarian cancer would further entrench MSD’s dominance in the PD-1 space.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced landmark results demonstrating ...
B96 to be featured in Presidential Symposium, underscoring the impact of KEYTRUDA® (pembrolizumab) in certain bladder and ovarian cancersData from multiple investigational medicines from Merck’s ...
Keytruda Qlex must be administered by a health care provider. The Food and Drug Administration (FDA) has approved Keytruda Qlex ™ (pembrolizumab and berahyaluronidase alfa-pmph) for patients aged 12 ...
Laurence is an avid writer, gamer, and traveller with several years of journalistic writing experience under his belt. Having helped create a student-focused magazine at university, he is keen to ...
Hosted on MSN
Merck's Keytruda gets an upgrade
CNBC's Angelica Peebles joins 'Squawk on the Street' with the latest news. Key takeaways from special elections in Arizona and Georgia Markets sold off after Powell said six words investors don’t want ...
In this article, we will be taking a look at the 10 Best Pharma Stocks to Buy According to Billionaires. Merck & Co., Inc. is placed fourth among them. Merck & Co., Inc. (NYSE:MRK), a global ...
Nvidia NVDA-4.40%decrease; red down pointing triangle and OpenAI, two U.S. giants powering America’s race for AI superintelligence, outlined an expansive partnership Monday, including plans for an ...
The U.S. Food and Drug Administration (FDA) on Friday approved Merck & Co. Inc.’s (NYSE:MRK) Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous administration in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback